IDEXX Laboratories, Inc. IDXX
Healthcare · Diagnostics & Research · United States · S&P 500
Based on the available data, IDEXX Laboratories, Inc. gets an algorithmic score of 51/100. It trades at 533.44 $, with a bearish technical trend (RSI 52.8) and 32.0% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- High ROE (74.2%): generates strong profit on equity.
- High net margin (25.0%): pricing power / competitive advantage.
- Low beta (0.62): defensive profile.
Weaknesses
- —
Fundamentals
| P/E | 37.49 |
| Forward P/E | 31.87 |
| PEG | 2.85 |
| P/B | 26.09 |
| EV/EBITDA | 26.47 |
| P/S | 9.24 |
| ROE % | 74.21 |
| ROA % | 27.08 |
| Gross margin % | 62.45 |
| Operating margin % | 34.98 |
| Net margin % | 25.03 |
| Revenue growth % (y/y) | 9.70 |
| Earnings growth % (y/y) | 17.60 |
| Revenue CAGR % | 8.52 |
| Earnings CAGR % | 15.98 |
| Debt/Equity % | 67.97 |
| Current ratio | 1.17 |
| FCF yield % | 2.48 |
| Dividend yield % | 0.00 |
| Payout % | 0.00 |
Returns
| 1 month | -3.9 % |
| 3 months | +1.3 % |
| 6 months | -4.2 % |
| YTD | -20.4 % |
| 1 year | -15.6 % |
| 3 years | +22.4 % |
| 5 years | -20.0 % |
Risk
| 1-year volatility | 32.0 % |
| Beta | 0.62 |
| 5-year max drawdown | -52.4 % |
| Sharpe 1A | -0.50 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.